POLY(D,L-LACTIDE-CO-GLYCOLIDE)/HYDROXYAPATITE CORE-SHELL NANOSPHERE. PT.2. SIMULTANEOUS RELEASE OF A DRUG AND A PRODRUG (CLINDAMYCIN AND CLINDAMYCIN PHOSPHATE)
Poly(D,L-lactide-co-glycolide)/hydroxyapatite (PLGA/HAp) core-shell nanostructures were used as the carrier of clindamycin-base, as a drug, and clindamycin-2-phosphate, as a prodrug model. As a result, a two-step release was observed: the controlled release of the more soluble phosphate form and the...
Gespeichert in:
| Veröffentlicht in: | Colloids and surfaces, B, Biointerfaces B, Biointerfaces, 2011-01, Vol.82 (2), p.414-421 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 421 |
|---|---|
| container_issue | 2 |
| container_start_page | 414 |
| container_title | Colloids and surfaces, B, Biointerfaces |
| container_volume | 82 |
| creator | Vukomanovic, M Skapin, S D Poljansek, I Zagar, E Kralj, B Ignjatovic, N Uskokovic, D |
| description | Poly(D,L-lactide-co-glycolide)/hydroxyapatite (PLGA/HAp) core-shell nanostructures were used as the carrier of clindamycin-base, as a drug, and clindamycin-2-phosphate, as a prodrug model. As a result, a two-step release was observed: the controlled release of the more soluble phosphate form and the sustained release of the less-soluble base form of clindamycin, resulting in a high overall concentration of the released drug during the period of 30 days in vitro. The HAp phase within the PLGA core-shells, applied as a drug carrier, delayed the process of the degradation of the polymer; however, the presence of the drug affected the process of degradation and this was the dominant factor in the control over the degradation of the polymer phase of PLGA/HAp and the consequent kinetics of the drug release. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_896184385</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1692365468</sourcerecordid><originalsourceid>FETCH-LOGICAL-p655-8990c1082fa32b40676d2f2773103ec92e58ecf4aca2781a6d004008f7d2b6123</originalsourceid><addsrcrecordid>eNp9jE9PgzAAxTlo4px-h95kiZ39A205NqUbJB0l0CVyWhiURDPdFPd5_KrO6cGTp_d-eb-8i2CCEsIh5yy-Cq7H8RkhRCLMJ8FnaU0TpvcGGqlcnmqoLFyaRllzgtlD1qSVfWxkKV3uNFC20rDOtDGgkIWty0xXeg5KNydzUOertXGy0HZdg0obLWsN7AJIkFbrJZBFeqplZc8UKpMXqVw1Ki_O018us-9r6fTsJrgc2t3ob39zGriFdiqDxi5zJQ08sDiGIklQh5EgQ0vJNkKMs54MhHOKEfVdQnwsfDdEbdcSLnDLeoQihMTAe7JlmNBpcPdze3jfvx39-LF5eRo7v9u1r35_HDciYVhEVMQnM_zXxCwhlMURE_QLtu1lmw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1692365468</pqid></control><display><type>article</type><title>POLY(D,L-LACTIDE-CO-GLYCOLIDE)/HYDROXYAPATITE CORE-SHELL NANOSPHERE. PT.2. SIMULTANEOUS RELEASE OF A DRUG AND A PRODRUG (CLINDAMYCIN AND CLINDAMYCIN PHOSPHATE)</title><source>Access via ScienceDirect (Elsevier)</source><creator>Vukomanovic, M ; Skapin, S D ; Poljansek, I ; Zagar, E ; Kralj, B ; Ignjatovic, N ; Uskokovic, D</creator><creatorcontrib>Vukomanovic, M ; Skapin, S D ; Poljansek, I ; Zagar, E ; Kralj, B ; Ignjatovic, N ; Uskokovic, D</creatorcontrib><description>Poly(D,L-lactide-co-glycolide)/hydroxyapatite (PLGA/HAp) core-shell nanostructures were used as the carrier of clindamycin-base, as a drug, and clindamycin-2-phosphate, as a prodrug model. As a result, a two-step release was observed: the controlled release of the more soluble phosphate form and the sustained release of the less-soluble base form of clindamycin, resulting in a high overall concentration of the released drug during the period of 30 days in vitro. The HAp phase within the PLGA core-shells, applied as a drug carrier, delayed the process of the degradation of the polymer; however, the presence of the drug affected the process of degradation and this was the dominant factor in the control over the degradation of the polymer phase of PLGA/HAp and the consequent kinetics of the drug release.</description><identifier>ISSN: 0927-7765</identifier><language>eng</language><subject>Carriers ; Degradation ; Drugs ; Hydroxyapatite ; Nanocomposites ; Nanomaterials ; Nanostructure ; Phosphates</subject><ispartof>Colloids and surfaces, B, Biointerfaces, 2011-01, Vol.82 (2), p.414-421</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids></links><search><creatorcontrib>Vukomanovic, M</creatorcontrib><creatorcontrib>Skapin, S D</creatorcontrib><creatorcontrib>Poljansek, I</creatorcontrib><creatorcontrib>Zagar, E</creatorcontrib><creatorcontrib>Kralj, B</creatorcontrib><creatorcontrib>Ignjatovic, N</creatorcontrib><creatorcontrib>Uskokovic, D</creatorcontrib><title>POLY(D,L-LACTIDE-CO-GLYCOLIDE)/HYDROXYAPATITE CORE-SHELL NANOSPHERE. PT.2. SIMULTANEOUS RELEASE OF A DRUG AND A PRODRUG (CLINDAMYCIN AND CLINDAMYCIN PHOSPHATE)</title><title>Colloids and surfaces, B, Biointerfaces</title><description>Poly(D,L-lactide-co-glycolide)/hydroxyapatite (PLGA/HAp) core-shell nanostructures were used as the carrier of clindamycin-base, as a drug, and clindamycin-2-phosphate, as a prodrug model. As a result, a two-step release was observed: the controlled release of the more soluble phosphate form and the sustained release of the less-soluble base form of clindamycin, resulting in a high overall concentration of the released drug during the period of 30 days in vitro. The HAp phase within the PLGA core-shells, applied as a drug carrier, delayed the process of the degradation of the polymer; however, the presence of the drug affected the process of degradation and this was the dominant factor in the control over the degradation of the polymer phase of PLGA/HAp and the consequent kinetics of the drug release.</description><subject>Carriers</subject><subject>Degradation</subject><subject>Drugs</subject><subject>Hydroxyapatite</subject><subject>Nanocomposites</subject><subject>Nanomaterials</subject><subject>Nanostructure</subject><subject>Phosphates</subject><issn>0927-7765</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp9jE9PgzAAxTlo4px-h95kiZ39A205NqUbJB0l0CVyWhiURDPdFPd5_KrO6cGTp_d-eb-8i2CCEsIh5yy-Cq7H8RkhRCLMJ8FnaU0TpvcGGqlcnmqoLFyaRllzgtlD1qSVfWxkKV3uNFC20rDOtDGgkIWty0xXeg5KNydzUOertXGy0HZdg0obLWsN7AJIkFbrJZBFeqplZc8UKpMXqVw1Ki_O018us-9r6fTsJrgc2t3ob39zGriFdiqDxi5zJQ08sDiGIklQh5EgQ0vJNkKMs54MhHOKEfVdQnwsfDdEbdcSLnDLeoQihMTAe7JlmNBpcPdze3jfvx39-LF5eRo7v9u1r35_HDciYVhEVMQnM_zXxCwhlMURE_QLtu1lmw</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Vukomanovic, M</creator><creator>Skapin, S D</creator><creator>Poljansek, I</creator><creator>Zagar, E</creator><creator>Kralj, B</creator><creator>Ignjatovic, N</creator><creator>Uskokovic, D</creator><scope>7SR</scope><scope>7U5</scope><scope>8BQ</scope><scope>8FD</scope><scope>JG9</scope><scope>L7M</scope><scope>7QO</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20110101</creationdate><title>POLY(D,L-LACTIDE-CO-GLYCOLIDE)/HYDROXYAPATITE CORE-SHELL NANOSPHERE. PT.2. SIMULTANEOUS RELEASE OF A DRUG AND A PRODRUG (CLINDAMYCIN AND CLINDAMYCIN PHOSPHATE)</title><author>Vukomanovic, M ; Skapin, S D ; Poljansek, I ; Zagar, E ; Kralj, B ; Ignjatovic, N ; Uskokovic, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p655-8990c1082fa32b40676d2f2773103ec92e58ecf4aca2781a6d004008f7d2b6123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Carriers</topic><topic>Degradation</topic><topic>Drugs</topic><topic>Hydroxyapatite</topic><topic>Nanocomposites</topic><topic>Nanomaterials</topic><topic>Nanostructure</topic><topic>Phosphates</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vukomanovic, M</creatorcontrib><creatorcontrib>Skapin, S D</creatorcontrib><creatorcontrib>Poljansek, I</creatorcontrib><creatorcontrib>Zagar, E</creatorcontrib><creatorcontrib>Kralj, B</creatorcontrib><creatorcontrib>Ignjatovic, N</creatorcontrib><creatorcontrib>Uskokovic, D</creatorcontrib><collection>Engineered Materials Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Materials Research Database</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Biotechnology Research Abstracts</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Colloids and surfaces, B, Biointerfaces</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vukomanovic, M</au><au>Skapin, S D</au><au>Poljansek, I</au><au>Zagar, E</au><au>Kralj, B</au><au>Ignjatovic, N</au><au>Uskokovic, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>POLY(D,L-LACTIDE-CO-GLYCOLIDE)/HYDROXYAPATITE CORE-SHELL NANOSPHERE. PT.2. SIMULTANEOUS RELEASE OF A DRUG AND A PRODRUG (CLINDAMYCIN AND CLINDAMYCIN PHOSPHATE)</atitle><jtitle>Colloids and surfaces, B, Biointerfaces</jtitle><date>2011-01-01</date><risdate>2011</risdate><volume>82</volume><issue>2</issue><spage>414</spage><epage>421</epage><pages>414-421</pages><issn>0927-7765</issn><abstract>Poly(D,L-lactide-co-glycolide)/hydroxyapatite (PLGA/HAp) core-shell nanostructures were used as the carrier of clindamycin-base, as a drug, and clindamycin-2-phosphate, as a prodrug model. As a result, a two-step release was observed: the controlled release of the more soluble phosphate form and the sustained release of the less-soluble base form of clindamycin, resulting in a high overall concentration of the released drug during the period of 30 days in vitro. The HAp phase within the PLGA core-shells, applied as a drug carrier, delayed the process of the degradation of the polymer; however, the presence of the drug affected the process of degradation and this was the dominant factor in the control over the degradation of the polymer phase of PLGA/HAp and the consequent kinetics of the drug release.</abstract><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0927-7765 |
| ispartof | Colloids and surfaces, B, Biointerfaces, 2011-01, Vol.82 (2), p.414-421 |
| issn | 0927-7765 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_896184385 |
| source | Access via ScienceDirect (Elsevier) |
| subjects | Carriers Degradation Drugs Hydroxyapatite Nanocomposites Nanomaterials Nanostructure Phosphates |
| title | POLY(D,L-LACTIDE-CO-GLYCOLIDE)/HYDROXYAPATITE CORE-SHELL NANOSPHERE. PT.2. SIMULTANEOUS RELEASE OF A DRUG AND A PRODRUG (CLINDAMYCIN AND CLINDAMYCIN PHOSPHATE) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T16%3A32%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=POLY(D,L-LACTIDE-CO-GLYCOLIDE)/HYDROXYAPATITE%20CORE-SHELL%20NANOSPHERE.%20PT.2.%20SIMULTANEOUS%20RELEASE%20OF%20A%20DRUG%20AND%20A%20PRODRUG%20(CLINDAMYCIN%20AND%20CLINDAMYCIN%20PHOSPHATE)&rft.jtitle=Colloids%20and%20surfaces,%20B,%20Biointerfaces&rft.au=Vukomanovic,%20M&rft.date=2011-01-01&rft.volume=82&rft.issue=2&rft.spage=414&rft.epage=421&rft.pages=414-421&rft.issn=0927-7765&rft_id=info:doi/&rft_dat=%3Cproquest%3E1692365468%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1692365468&rft_id=info:pmid/&rfr_iscdi=true |